LivaNova (NASDAQ:LIVN) Issues FY24 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.05-3.15 for the period, compared to the consensus EPS estimate of $3.00. LivaNova also updated its FY 2024 guidance to 3.050-3.150 EPS.

LivaNova Stock Performance

NASDAQ:LIVN traded up $1.23 during trading hours on Friday, reaching $64.15. The stock had a trading volume of 891,504 shares, compared to its average volume of 781,875. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.51 and a current ratio of 3.17. The stock has a 50 day simple moving average of $54.57 and a 200 day simple moving average of $50.94. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.36. The stock has a market cap of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28. The company had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 earnings per share. On average, research analysts forecast that LivaNova will post 3.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several recent research reports. Robert W. Baird lifted their price target on LivaNova from $58.00 to $66.00 and gave the company a neutral rating in a research report on Thursday. Barclays lifted their price target on LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research report on Monday, February 26th. Needham & Company LLC reiterated a buy rating and issued a $72.00 price target on shares of LivaNova in a research report on Wednesday. StockNews.com raised LivaNova from a hold rating to a buy rating in a research note on Thursday, April 25th. Finally, Mizuho lifted their price objective on LivaNova from $75.00 to $80.00 and gave the company a buy rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $66.20.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.